scholarly journals In Vitro and in Vivo Regulation of Antioxidant Response Element-Dependent Gene Expression by Estrogens

Endocrinology ◽  
2004 ◽  
Vol 145 (1) ◽  
pp. 311-317 ◽  
Author(s):  
P. J. Ansell ◽  
C. Espinosa-Nicholas ◽  
E. M. Curran ◽  
B. M. Judy ◽  
B. J. Philips ◽  
...  
Keyword(s):  
Gene Expression ◽  
Phase Ii ◽  
Enzyme Activities ◽  
Antioxidant Response ◽  
Quinone Reductase ◽  
Antioxidant Response Element ◽  
Phase Ii Enzyme ◽  
17Β Estradiol

Abstract Understanding estrogen’s regulation of phase II detoxification enzymes is important in explaining how estrogen exposure increases the risk of developing certain cancers. Phase II enzymes such as glutathione-S-transferases (GST) and quinone reductase protect against developing chemically induced cancers by metabolizing reactive oxygen species. Phase II enzyme expression is regulated by a cis-acting DNA sequence, the antioxidant response element (ARE). It has previously been reported that several antiestrogens, but not 17β-estradiol, could regulate ARE-mediated gene transcription. Our goal was to determine whether additional estrogenic compounds could regulate ARE-mediated gene expression both in vitro and in vivo. We discovered that physiological concentrations (10 nm) of 17β-estradiol repressed GST Ya ARE-dependent gene expression in vitro. Treatment with other endogenous and anti-, xeno-, and phytoestrogens showed that estrogen receptor/ARE signaling is ligand, receptor subtype, and cell type specific. Additionally, GST and quinone reductase activities were significantly lowered in a dose-dependent manner after 17β-estradiol exposure in the uteri of mice. In conclusion, we have shown that 17β-estradiol, and other estrogens, down-regulate phase II enzyme activities. We propose estrogen-mediated repression of phase II enzyme activities may increase cellular oxidative DNA damage that ultimately can result in the formation of cancer in some estrogen-responsive tissues.

scholarly journals Induction of the Protective Antioxidant Response Element Pathway by 6-Hydroxydopamine In Vivo and In Vitro

2005 ◽  
Vol 87 (1) ◽  
pp. 176-186 ◽  
Author(s):  
Rebekah J. Jakel ◽  
Jonathan T. Kern ◽  
Delinda A. Johnson ◽  
Jeffrey A. Johnson
Keyword(s):  
Antioxidant Response ◽  
Antioxidant Response Element ◽  
Response Element ◽  
6 Hydroxydopamine

Preclinical Investigations Demonstrate Effectiveness of Aplidin in Acute Leukemias and Lymphomas and Provide the Basis for Further Clinical Studies.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4496-4496
Author(s):  
Debabrata Banerjee ◽  
Guray Saydam ◽  
Lata G. Menon ◽  
Giuseppe S.A. Longo ◽  
Daniel Medina ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cell Lines ◽  
Phase Ii ◽  
Myeloid Leukemia ◽  
Xenograft Model ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Leukemias And Lymphomas

Abstract Aplidin (dehydrodidemnin B, C57H89N7O15) (APLD) is a novel antitumor agent isolated from the Mediterranean tunicate (seasquirt) Aplidium albicans. APLD has shown impressive in vitro and in vivo activity against different human cancer cells and has recently entered Phase II clinical trials in a variety of solid tumors following promising toxicity and pharmacological properties seen in Phase I studies. Fatigue and muscular pain were the most prevalent toxicities at 5 mg/m2 iv 3 h every other week or 3.4 mg/m2/wk with little or no bone marrow toxicity. APLD inhibits protein synthesis via GTP-dependent elongation factors 1-alpha and ornithine decarboxylase (ODC) activity, induces rapid p53-independent apoptosis in vitro, cell cycle perturbation and alteration of gene expression at early times after treatment. APLD inhibits vascular endothelial growth factor (VEGF) secretion and vascular endothelial growth factor-receptor 1 (VEGF-R1/flt-1), preventing autocrine stimulation in the human lymphoid leukemic cell line MOLT-4 cells and in AML blasts. APLD is a potent inhibitor of human myeloid leukemia cell lines (K-562, HEL and HL60), as well as fresh blast cells obtained from patients with both ALL and AML and is more potent than Idarubicin. Cytototoxic doses effective against multiple myeloma cells and fresh pediatric and adult ALL/AML blasts are achievable in plasma and are well below the recommended dose, thus a positive therapeutic index is anticipated. Moreover, the lack of cross resistance with conventional agents against fresh pediatric and adult AML/ALL blasts except fludarabine and Gemcitabine makes APLD an attractive therapeutic choice. Characterization of gene expression profile is currently underway in an attempt to generate a molecular fingerprint of sensitivity/resistance to APLD that will be validated in phase II clinical studies. Based on in vitro antileukemic effect of APLD as well as early results of clinical trials, a systematic study of drug combinations with Aplidin (APLD), for use possible in hematologic malignancies was undertaken. Three cell lines viz. K562 (acute myeloid leukemia), CCRF-CEM (acute lymphocytic leukemia), and SKI-DLCL (diffuse large cell lymphoma) were used for combination studies. Cytarabine and mitoxantrone were found to be synergistic in combination with APLD in all 3 cell lines as assessed by the Chou-Talalay combination index analysis. Since cytarabine and APLD produced impressive synergistic cell kill in all three cell culture models, the combination was further tested in the CCRF-CEM ALL xenograft model in SCID mice. APLD (0.7 mg/Kg) potentiated the antitumoral effect of cytarabine (50mg/Kg) in vivo. Addition of APLD to cytarabine treatment in xenograft model resulted in greater than 50% reduction in tumor size as compared to the untreated group. T/C ratios indicated that the effect of the combination was maximal at day 5 but was still maintained on day 8 (T/C on day 3 = 0.614; day 5= 0.403 and day 8= 0.703). The preclinical results with APLD in leukemias and lymphomas, as a single agent and in combination with cytarabine provide the basis for implementation of a phase II program in resistant relapsed leukemias and lymphomas.

scholarly journals Ginseng Berry Extract Prevents Atherogenesis via Anti-Inflammatory Action by Upregulating Phase II Gene Expression

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Chun-Ki Kim ◽  
Dong Hui Cho ◽  
Kyu-Sun Lee ◽  
Dong-Keon Lee ◽  
Chan-Woong Park ◽  
...  
Keyword(s):  
Gene Expression ◽  
Phase Ii ◽  
Underlying Mechanism ◽  
Suppressive Effect ◽  
Heme Oxygenase 1 ◽  
Cellular Events ◽  
Atherosclerotic Lesions ◽  
Species Production

Ginseng berry possesses higher ginsenoside content than its root, which has been traditionally used in herbal medicine for many human diseases, including atherosclerosis. We here examined the antiatherogenic effects of the Korean ginseng berry extract (KGBE) and investigated its underlying mechanism of actionin vitroandin vivo. Administration of KGBE decreased atherosclerotic lesions, which was inversely correlated with the expression levels of phase II genes to include heme oxygenase-1 (HO-1) and glutamine-cysteine ligase (GCL). Furthermore, KGBE administration suppressed NF-κB-mediated expression of atherogenic inflammatory genes (TNF-α, IL-1β, iNOS, COX-2, ICAM-1, and VCAM-1), without altering serum cholesterol levels, in ApoE-/-mice fed a high fat-diet. Treatment with KGBE increased phase II gene expression and suppressed lipopolysaccharide-induced reactive oxygen species production, NF-κB activation, and inflammatory gene expression in primary macrophages. Importantly, these cellular events were blocked by selective inhibitors of HO-1 and GCL. In addition, these inhibitors reversed the suppressive effect of KGBE on TNF-α-mediated induction of ICAM-1 and VCAM-1, resulting in decreased interaction between endothelial cells and monocytes. These results suggest that KGBE ameliorates atherosclerosis by inhibiting NF-κB-mediated expression of atherogenic genes via upregulation of phase II enzymes and thus has therapeutic or preventive potential for atherosclerosis.

scholarly journals Memo1 gene expression in kidney and bone is unaffected by dietary mineral load and calciotropic hormones

2020 ◽  
Author(s):  
Matthias B. Moor ◽  
Olivier Bonny
Keyword(s):  
Gene Expression ◽  
Vitamin D ◽  
Phenotypic Traits ◽  
Dietary Interventions ◽  
Calciotropic Hormones ◽  
Genes Expression ◽  
17Β Estradiol ◽  
And Control

AbstractMediator of Cell Motility 1 (MEMO1) is an ubiquitously expressed modulator of cellular responses to growth factors including FGF23 signaling, and Memo1-deficient mice share some phenotypic traits with Fgf23- or Klotho-deficient mouse models. Here, we tested whether Memo1 gene expression is regulated by calciotropic hormones or by changing the dietary mineral load.MLO-Y4 osteocyte-like cells were cultured and treated with 1,25(OH)2-vitamin D3. Wildtype C57BL/6N mice underwent treatments with 1,25(OH)2-vitamin D3, parathyroid hormone (PTH), 17β-estradiol or vehicle. Other cohorts of C57BL/6N mice were fed diets varying in calcium or phosphate content. Expression of Memo1 and control genes was assessed by qPCR.1,25(OH)2-vitamin D3 caused an acute decrease in Memo1 transcript levels in vitro, but not in vivo. None of the hormones tested had an influence on Memo1 transcripts, whereas the assessed control genes reacted the expected way. Dietary interventions with calcium and phosphate did not affect Memo1 transcripts but altered the chosen control genes’ expression.We observed that Memo1 was not regulated by calciotropic hormones or change in mineral load, suggesting major differences between the regulation and physiological roles of Klotho, Fgf23 and Memo1.

scholarly journals Μελέτη του μεταγραφικού παράγοντα Nrf2 ως διαμεσολαβητή της δράσης των στατινών

2010 ◽  
Author(s):  
Διονύσιος Χαρτουμπέκης
Keyword(s):  
Glutathione Peroxidase ◽  
Heme Oxygenase ◽  
Antioxidant Response ◽  
Heme Oxygenase 1 ◽  
Related Factor ◽  
Antioxidant Response Element ◽  
Response Element

Τα ευεργετικά αποτελέσματα των αναστολέων της αναγωγάσης του HMG-CoA (3-υδροξυ-3-μεθυλ-γλουταρυλ-συνένζυμο Α) έχουν αποδοθεί όχι μόνο στη μείωση των επιπέδων χοληστερόλης αλλά και στις πλειοτροπικές τους δράσεις και ιδιαίτερα στις αντιοξειδωτικές τους δράσεις. Ο Nrf2 (NF-E2-related factor 2) είναι ένας μεταγραφικός παράγοντας που ενορχηστρώνει τη μεταγραφική απάντηση των κυττάρων στο οξειδωτικό στρες και σε ηλεκτροφιλικά ξενοβιοτικά με την έκφραση αντιοξειδωτικών-κυτταροπροστατευτικών γονιδίων. Στην παρούσα μελέτη, χρησιμοποιήθηκαν επίμυες Wistar, πρωτογενείς καλλιέργειες ηπατοκυττάρων, ST-2 κύτταρα και πρωτογενείς εμβρυϊκοί ινοβλάστες από μυς C57BL6J αγρίου τύπου (WT) ή με απαλοιφή του Nrf2 (KO-Nrf2) για τη μελέτη του ρόλου του Nrf2 στη διαμεσολάβηση των αντιοξειδωτικών δράσεων των στατινών. Η σιμβαστατίνη ενεργοποίησε τον Nrf2, δηλαδή οδήγησε στη μετακίνησή του στον πυρήνα στο ήπαρ επίμυων και σε πρωτογενή καλλιέργεια ηπατοκυττάρων. Η ανωτέρω δράση ήταν εξαρτώμενη από το μεβαλονικό και ανεξάρτητη από τη χοληστερόλη. Σε πυρηνικά πρωτεϊνικά εκχυλίσματα από ήπαρ επίμυων που έλαβαν σιμβαστατίνη, η μεταγραφική ενεργότητα του Nrf2 αυξήθηκε σημαντικά και το mRNA δύο γνωστών στόχων του Nrf2, ΗΟ-1 (Heme Oxygenase 1) και GPX-2 (Glutathione Peroxidase 2) αυξήθηκε. Σε ST-2 κύτταρα μόνιμα διαμολυσμένα με πλασμίδιο που φέρει αλληλουχία DNA στην οποία προσκολλάται ο Nrf2 (ARE-Antioxidant Response Element) (ARE-ST2 κύτταρα), η σιμβαστατίνη αύξησε τη μεταγραφική ενεργότητα του Nrf2 με τρόπο εξαρτώμενο από το μεβαλονικό και ανεξάρτητο από τη χοληστερόλη. Επίσης, χρησιμοποιώντας πρωτογενείς καλλιέργειες εμβρυϊκών ινοβλαστών από μυς WT και ΚΟ-Nrf2 και μετρώντας τα επίπεδα των αντιδραστικών ειδών οξυγόνου (ROS) μετά από επώαση με οξειδάση της γλυκόζης έπειτα από επίδραση ή μη με σιμβαστατίνη, διαπιστώθηκε ότι η σιμβαστατίνη μειώνει τα επίπεδα των παραχθέντων ROS στους WT ινοβλάστες και όχι σε μεγάλο βαθμό στους KO-Nrf2 ινοβλάστες. Τέλος, με τη χρήση αναστολέων του μονοπατιού της PI3K/Akt σε ARE-ST2 κύτταρα στα οποία είχαμε επιδράσει με σιμβαστατίνη, διαπιστώθηκε ότι αίρεται σε μεγάλο βαθμό η ενεργοποίηση του Nrf2 από τη σιμβαστατίνη. Στην παρούσα μελέτη παρουσιάζεται για πρώτη φορά α) η ενεργοποίηση του Keap1/Nrf2 σηματοδοτικού μονοπατιού σε in vivo και in vitro μοντέλα από τη σιμβαστατίνη με τρόπο εξαρτώμενο από το μεβαλονικό και ανεξάρτητο από τη χοληστερόλη και β) ότι η σιμβαστατίνη μειώνει τα παραγόμενα αντιδραστικά είδη οξυγόνου (ROS) μέσω της ενεργοποίησης του Nrf2 διαμέσου του μοριακού μονοπατιού της PI3K/Akt. H ενεργοποίηση αυτή του Nrf2 από τη σιμβαστατίνη εκτός του ότι προσφέρει αποτελεσματική προστασία του κυττάρου από τις δυσμενείς επιπτώσεις του οξειδωτικού στρες, εξηγεί και μέρος των πλειοτροπικών δράσεων των στατινών.

Sign in / Sign up

Export Citation Format

Share Document